Corporate R&D StrategyNVIDIA's BioNeMo Becomes Pharma's AI Backbone as Novo Nordisk Offloads Parkinson's Risk to AI PartnerSalvado•Jun 27, 2026
Healthcare & BiotechNovo Nordisk Exits Internal Parkinson's Unit, Licenses Program to AI Partner Cellular IntelligenceSalvado•Jun 25, 2026
Corporate StrategyNovo Nordisk Exits Cell Therapy, Hands Parkinson's Assets to AI Startup as Pharma Rewires R&DSalvado•Jun 19, 2026
Corporate StrategyNovo Nordisk Outsources Parkinson's R&D to AI Partner as Big Pharma Drops Vertical IntegrationSalvado•Jun 9, 2026
Pharmaceutical StrategyNovo Nordisk Licenses Parkinson's Cell Therapy to AI Partner, Shutters Internal UnitSalvado•Jun 5, 2026
Corporate StrategyNovo Nordisk Licenses Cell Therapy to AI Spinout as Big Pharma Rewrites Its R&D PlaybookSalvado•Jun 1, 2026
Pharma StrategyNovo Nordisk's 24.9% Rally Validates AI Licensing Over Internal Cell TherapySalvado•May 31, 2026
Corporate PartnershipsNVIDIA's BioNeMo Becomes Pharma's Shared AI Backbone as Platform Race With Specialized Rivals Heats UpSalvado•May 27, 2026
Corporate StrategyNovo Nordisk Closes Internal Cell Therapy Unit, Licenses Program to AI-Native Cellular IntelligenceSalvado•May 21, 2026
Corporate Strategy & Business TransformationNovo Nordisk's 25% Stock Surge Validates Pharma's Pivot to AI Platform OutsourcingSalvado•May 18, 2026
Pharma FinanceNovo Nordisk Licenses Parkinson's Program and Exits Cell Therapy as AI Reshapes Pharma R&DSalvado•May 16, 2026
Pharma & HealthcareNovo Nordisk's 24.9% Stock Surge Validates Pharma's Pivot From Internal R&D to AI PartnershipsSalvado•May 13, 2026
